Ebola Ebola Virus
Conditions
Interventions
Brincidofovir (BCV)
Historical untreated survival rate
Sponsors
University of Oxford
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Male and female patients 2 months of age or older Laboratory confirmed infection with Ebolavirus infection. Women who are lactating must agree to stop breastfeeding (a standard recommendation for all EVD patients) Willingness to use barrier birth control for 3 months after recovery of EVD (a standard recommendation for all EVD patients) For patients 18 years and older: the ability to provide fully informed consent or the provision of consent from the representative of a patient deemed too unwell to comprehend what is being asked of them. For patients under 18 years: consent from a parent or guardian.
Exclusion criteria
Exclusion criteria: Any underlying disease or condition that, in the opinion of the principal investigator or treating physician, could jeopardize the participant¿s or healthcare workers safety or the participant¿s ability to comply with the protocol requirements Patient unable to take oral IMP (e.g. severe vomiting unresponsive to anti-emetics, unconscious) Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mortality at Day 14 after entry into the trial | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to meeting EVD treatment center discharge criteria;Mortality at Day 30 after first dose of study treatment;Day 4 viral load ;Presence and duration of symptoms;Convalescent anti-Ebolavirus IgG titer ;Incidence of SARs and key adverse events | — |
Countries
Liberia
Contacts
Public ContactRaul Pardinaz-Solis
University of Oxford
Outcome results
None listed